{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T07:56:43Z","timestamp":1781164603477,"version":"3.54.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.lungcan.2026.109354","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:39:39Z","timestamp":1778153979000},"page":"109354","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["MORPHEUS-Lung: biomarkers and clinical response to atezolizumab\u00a0+\u00a0bevacizumab\u00a0+\u00a0stereotactic body radiotherapy in patients with metastatic non-small cell lung cancer"],"prefix":"10.1016","volume":"217","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5562-270X","authenticated-orcid":false,"given":"Byoung Chul","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Min","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5384-1687","authenticated-orcid":false,"given":"Sang Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1407-2369","authenticated-orcid":false,"given":"Dong Kwon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Pardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hen","family":"Prizant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaacov R.","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nedal","family":"Al-Sakaff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Joachim","family":"Helms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Velimir","family":"Gayevskiy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barzin Y.","family":"Nabet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Pintoffl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Ghiringhelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2026.109354_b0005","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2147\/CMAR.S187317","article-title":"Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades","volume":"11","author":"Lu","year":"2019","journal-title":"Cancer Manag. Res."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109354_b0010","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35476","article-title":"Survival trends among patients with metastatic non-small cell lung cancer before and after the approval of immunotherapy in the United States: a surveillance, epidemiology, and end results database-based study","volume":"131","author":"Wang","year":"2025","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2026.109354_b0015","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","article-title":"Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.109354_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103538","article-title":"Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy?","volume":"169","author":"Insa","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"8","key":"10.1016\/j.lungcan.2026.109354_b0025","volume":"13","author":"Francois","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"9","key":"10.1016\/j.lungcan.2026.109354_b0030","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/nm0901-987","article-title":"Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy","volume":"7","author":"Jain","year":"2001","journal-title":"Nat. Med."},{"issue":"18","key":"10.1016\/j.lungcan.2026.109354_b0035","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1158\/1078-0432.CCR-18-1543","article-title":"The intersection between tumor angiogenesis and immune suppression","volume":"25","author":"Rahma","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109354_b0040","doi-asserted-by":"crossref","first-page":"12624","DOI":"10.1038\/ncomms12624","article-title":"Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma","volume":"7","author":"Wallin","year":"2016","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109354_b0045","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109354_b0050","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1001\/jamaoncol.2022.5959","article-title":"Atezolizumab plus bevacizumab as first-line treatment for patients with metastatic nonsquamous non-small cell lung cancer with high tumor mutation burden: a nonrandomized controlled trial","volume":"9","author":"Provencio","year":"2023","journal-title":"JAMA Oncol."},{"issue":"21","key":"10.1016\/j.lungcan.2026.109354_b0055","doi-asserted-by":"crossref","first-page":"7985","DOI":"10.1158\/0008-5472.CAN-04-1525","article-title":"Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes","volume":"64","author":"Garnett","year":"2004","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109354_b0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032542","article-title":"Chemotherapeutics and radiation stimulate MHC class I expression through elevated interferon-beta signaling in breast cancer cells","volume":"7","author":"Wan","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.lungcan.2026.109354_b0065","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3389\/fimmu.2019.00193","article-title":"Role of radiation therapy in modulation of the tumor stroma and microenvironment","volume":"10","author":"Menon","year":"2019","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109354_b0070","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nrc.2018.6","article-title":"Using immunotherapy to boost the abscopal effect","volume":"18","author":"Ngwa","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"9","key":"10.1016\/j.lungcan.2026.109354_b0075","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","article-title":"Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial","volume":"5","author":"Theelen","year":"2019","journal-title":"JAMA Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109354_b0080","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/cncr.32468","article-title":"Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC)","volume":"126","author":"Bodor","year":"2020","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2026.109354_b0085","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.ijrobp.2022.03.015","article-title":"Prognostic and predictive role of PD-L1 expression in stage III non-small cell lung cancer treated with definitive chemoradiation and adjuvant durvalumab","volume":"113","author":"Bryant","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.lungcan.2026.109354_b0090","article-title":"T lymphocyte heterogeneity in NSCLC: implications for biomarker development and therapeutic innovation","volume":"16","author":"Liu","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lungcan.2026.109354_b0095","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ejca.2020.10.017","article-title":"Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy","volume":"145","author":"Gataa","year":"2021","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2026.109354_b0100","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1158\/1078-0432.CCR-14-1187","article-title":"Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer","volume":"21","author":"Anagnostou","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109354_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101134","article-title":"The association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: a systematic review and meta-analysis","volume":"41","author":"Li","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"4","key":"10.1016\/j.lungcan.2026.109354_b0110","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1159\/000438523","article-title":"Prognostic role of tumor-infiltrating lymphocytes in lung cancer: a meta-analysis","volume":"37","author":"Geng","year":"2015","journal-title":"Cell. Physiol. Biochem."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109354_b0115","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s43018-021-00292-8","article-title":"Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer","volume":"3","author":"Liu","year":"2022","journal-title":"Nat Cancer."},{"issue":"7","key":"10.1016\/j.lungcan.2026.109354_b0120","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.4049\/jimmunol.1402711","article-title":"CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients","volume":"194","author":"Djenidi","year":"2015","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.lungcan.2026.109354_b0125","article-title":"CD103(+)CD8(+) T(RM) cells accumulate in tumors of anti-PD-1-responder lung cancer patients and are tumor-reactive lymphocytes enriched with Tc17","volume":"1","author":"Corgnac","year":"2020","journal-title":"Cell Rep. Med."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109354_b0130","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1159\/000515305","article-title":"Exploring markers of exhausted CD8 T cells to predict response to immune checkpoint inhibitor therapy for hepatocellular carcinoma","volume":"10","author":"Hsu","year":"2021","journal-title":"Liver Cancer."},{"issue":"12","key":"10.1016\/j.lungcan.2026.109354_b0135","article-title":"Analysis of PD1, LAG3, TIGIT, and TIM3 expression in human lung adenocarcinoma reveals a 25-gene signature predicting immunotherapy response","volume":"5","author":"Guegan","year":"2024","journal-title":"Cell Rep. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109354_b0140","doi-asserted-by":"crossref","first-page":"7825","DOI":"10.1038\/s41467-023-43381-1","article-title":"PD-1(-) CD45RA(+) effector-memory CD8 T cells and CXCL10(+) macrophages are associated with response to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma","volume":"14","author":"Cappuyns","year":"2023","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109354_b0145","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/1078-0432.CCR-19-1868","article-title":"Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade","volume":"26","author":"House","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109354_b0150","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.immuni.2019.04.010","article-title":"Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of anti-PD-1 therapy","volume":"50","author":"Chow","year":"2019","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.lungcan.2026.109354_b0155","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1111\/cas.15751","article-title":"Involvement of protumor macrophages in breast cancer progression and characterization of macrophage phenotypes","volume":"114","author":"Komohara","year":"2023","journal-title":"Cancer Sci."},{"issue":"10","key":"10.1016\/j.lungcan.2026.109354_b0160","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41419-024-07074-x","article-title":"Novel FABP4(+)C1q(+) macrophages enhance antitumor immunity and associated with response to neoadjuvant pembrolizumab and chemotherapy in NSCLC via AMPK\/JAK\/STAT axis","volume":"15","author":"Zhang","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.lungcan.2026.109354_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101827","article-title":"Impact of genetic variants involved in the lipid metabolism pathway on progression free survival in patients receiving bevacizumab-based chemotherapy in metastatic colorectal cancer: a retrospective analysis of FIRE-3 and MAVERICC trials","volume":"57","author":"Wang","year":"2023","journal-title":"EClinicalMedicine"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226004150?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226004150?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T07:00:20Z","timestamp":1781161220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226004150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":33,"alternative-id":["S0169500226004150"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109354","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MORPHEUS-Lung: biomarkers and clinical response to atezolizumab\u00a0+\u00a0bevacizumab\u00a0+\u00a0stereotactic body radiotherapy in patients with metastatic non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109354","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109354"}}